Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.085 +0.005 (+0.46%)
Streaming Delayed Price Updated: 9:31 AM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Why Is Paycom Software (PAYC) Stock Down 39% Today? ↗
Paycom Software stock is falling hard on Wednesday as investors in PAYC go over the company's mixed earnings report for Q3 2023! 
Via InvestorPlace
News headline image
Why Is Mainz Biomed (MYNZ) Stock Moving Today? ↗
Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today! 
Via InvestorPlace
News headline image
Today's Pharma Tales Of Loss And Success: Pfizer Swings To A Quarterly Loss And Mainz Biomed Reports Positive Interim Screening Campaign Results ↗
As it struggles to navigate the rapid decline of its Covid-19 fame, Pfizer Inc (NYSE: PFE) reported a quarterly loss for the third quarter. 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Mainz Biomed ↗
 
Via Benzinga
News headline image
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine ↗
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical... 
Via Benzinga
News headline image
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Big Pharma Could Transform Into BioTech Pharma ↗
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall... 
Via Benzinga
News headline image
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe ↗
While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated. 
Via Benzinga
News headline image
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine ↗
Pharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in... 
Via Benzinga
News headline image
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
From Mainz BioMed NV
Via GlobeNewswire
News headline image
AI To Revolutionize Clinical Trials And Diagnostics ↗
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
News headline image
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention ↗
By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology... 
Via Benzinga
News headline image
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket ↗
Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! 
Via InvestorPlace
News headline image
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
From Mainz BioMed NV
Via GlobeNewswire
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
--News Direct-- 
Via News Direct
News headline image
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle ↗
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
News headline image
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar ↗
The WHO reports that colorectal cancer is the second most fatal cancer around the world. 
Via Benzinga
News headline image
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
From Mainz BioMed NV
Via GlobeNewswire
Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible
--News Direct-- 
Via News Direct
News headline image
Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech ↗
Colorectal cancer is the third most common cancer worldwide, and although the majority of colorectal cancer cases have historically occurred in individuals aged 45 and older, it is increasingly... 
Via Benzinga
News headline image
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.